Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice-Reference-Cited by-同舟云学术

Insights into the Use of Peripherally Acting μ-Opioid Receptor Antagonists (PAMORAs) in Oncologic Patients: from Scientific Evidence to Real Clinical Practice

Published:2021-02-26 Issue:3 Volume:22 Page:
ISSN:1527-2729
Container-title:Current Treatment Options in Oncology
language:en
Short-container-title:Curr. Treat. Options in Oncol.

Author:

Fernández-Montes Ana,de Velasco Guillermo,Aguín Santiago,Farriols Cristina,Guirado-Risueño María,Jerviz-Guía Vanessa G.,Baeza-Nadal María Victoria,Chicas-Sett Rodolfo,Fírvida José Luis,García-Navalón Francisco,Martín Patricia,Perezagua-Marín Carmen,Rodríguez Dulce,Santamaría Joan,Saurí Tamara,Cobo Manuel

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Oncology

Link

http://link.springer.com/content/pdf/10.1007/s11864-021-00816-5.pdf

Reference65 articles.

1. Hughes PA, et al. Opioidergic effects on enteric and sensory nerves in the lower GI tract: basic mechanisms and clinical implications. Am J Physiol Gastrointest Liver Physiol. 2016;311(3):G501–13.

2. Azizi Z, Javid Anbardan S, Ebrahimi Daryani N. A review of the clinical manifestations, pathophysiology and management of opioid bowel dysfunction and narcotic bowel syndrome. Middle East J Dig Dis. 2014;6(1):5–12.

3. •• Larkin PJ, et al. Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines. Ann Oncol. 2018;29(Suppl 4):iv111–25 ESMO Clinical Practice Guidelines that highlights the impact of constipation and discuss pharmacological and non-pharmacological options for management, as well as the challenges of treatments in older cancer patients at enhanced risk of constipation.

4. •• Farmer AD, et al. Pathophysiology and management of opioid-induced constipation: European expert consensus statement. United European Gastroenterol J. 2019;7(1):7–20 An European expert panel evaluates current evidence in the literature regarding pathophysiology and clinical evaluation of OIC, the importance of early OIC recognition and the need of combined therapies as well as provides a management algorithm for day-to-day clinical practice.

5. Bell TJ, et al. The prevalence, severity, and impact of opioid-induced bowel dysfunction: results of a US and European Patient Survey (PROBE 1). Pain Med. 2009;10(1):35–42.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Will I soon be out of my job? Quality and guideline conformity of ChatGPT therapy suggestions to patient inquiries with gynecologic symptoms in a palliative setting;Archives of Gynecology and Obstetrics;2023-11-17

2. Antagonists of the Mu-Opioid Receptor in the Cancer Patient: Fact or Fiction?;Current Oncology Reports;2022-06-01

3. A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation—The NACASY Study;Cancers;2022-02-23

4. Pharmacological characterization of naloxegol: In vitro and in vivo studies;European Journal of Pharmacology;2021-07